Allergan Plc’s Vraylar has been approved by the U.S. Food and Drug administration to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition.
Vraylar is an approved treatment in the United States for schizophrenia in adults and for manic or mixed episodes associated with bipolar I disorder.
Allergan recently experienced a clinical failure for its potential blockbuster depression treatment, rapastinel,.
Vraylar is being tested as a treatment for autism as well as an add-on treatment for major depressive disorder.
Read the Reuters report